Have a feature idea you'd love to see implemented?
Let us know!
NTLA Intellia Therapeutics Inc
Price (delayed)
$15.85
Market cap
$1.61B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.48
Enterprise value
$1.59B
Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron.
Highlights
The company's debt fell by 13% YoY and by 4.1% QoQ
The company's quick ratio fell by 27% YoY and by 21% QoQ
Intellia Therapeutics's revenue has decreased by 13% YoY and by 13% QoQ
Key stats
What are the main financial stats of NTLA
Market
Valuations
Earnings
Shares outstanding
101.58M
Market cap
$1.61B
Enterprise value
$1.59B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.57
Price to sales (P/S)
33.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.49
Revenue
$45.97M
EBIT
-$508.8M
EBITDA
-$498.93M
Free cash flow
-$382.65M
Per share
Balance sheet
Liquidity
EPS
-$5.48
Free cash flow per share
-$3.95
Book value per share
$10.07
Revenue per share
$0.47
TBVPS
$12.29
Total assets
$1.19B
Total liabilities
$220.47M
Debt
$106.3M
Equity
$971.06M
Working capital
$652.12M
Debt to equity
0.11
Current ratio
7.21
Quick ratio
6.69
Net debt/EBITDA
0.05
Margins
Efficiency
Dividend
EBITDA margin
-1,085.4%
Gross margin
100%
Net margin
-1,106.9%
Operating margin
-1,140%
Return on assets
-40.7%
Return on equity
-49.7%
Return on invested capital
-46.9%
Return on capital employed
-46.8%
Return on sales
-1,106.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NTLA stock price
How has the Intellia Therapeutics stock price performed over time
Intraday
-20.51%
1 week
-24.45%
1 month
-26.18%
1 year
-40.5%
YTD
-48.02%
QTD
-22.87%
Financial performance
How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$45.97M
Gross profit
$45.97M
Operating income
-$524.05M
Net income
-$508.8M
Gross margin
100%
Net margin
-1,106.9%
Intellia Therapeutics's operating margin has decreased by 31% YoY and by 16% QoQ
The company's net margin fell by 29% YoY and by 20% QoQ
The company's operating income fell by 14% YoY
Intellia Therapeutics's revenue has decreased by 13% YoY and by 13% QoQ
Growth
What is Intellia Therapeutics's growth rate over time
Valuation
What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
1.57
P/S
33.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.49
The EPS has contracted by 2.2% from the previous quarter
The stock's P/B is 70% below its 5-year quarterly average of 5.3 and 37% below its last 4 quarters average of 2.5
Intellia Therapeutics's equity has decreased by 12% YoY and by 6% from the previous quarter
The price to sales (P/S) is 65% lower than the 5-year quarterly average of 96.5 and 41% lower than the last 4 quarters average of 56.5
Intellia Therapeutics's revenue has decreased by 13% YoY and by 13% QoQ
Efficiency
How efficient is Intellia Therapeutics business performance
The ROS has contracted by 29% YoY and by 20% from the previous quarter
The ROA has contracted by 20% YoY and by 7% from the previous quarter
Intellia Therapeutics's ROE has decreased by 19% YoY and by 8% from the previous quarter
Intellia Therapeutics's ROIC has decreased by 9% YoY and by 8% from the previous quarter
Dividends
What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NTLA.
Financial health
How did Intellia Therapeutics financials performed over time
The company's quick ratio fell by 27% YoY and by 21% QoQ
NTLA's current ratio is down by 23% year-on-year and by 20% since the previous quarter
The company's debt is 89% lower than its equity
The company's debt fell by 13% YoY and by 4.1% QoQ
Intellia Therapeutics's equity has decreased by 12% YoY and by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.